Similarly, the clinical response rate is very low even in patients receiving anti-CTLA4 therapy for unresectable or metastatic melanoma (the first approved indication of anti-CTLA4 therapy) (Savoia et al., 2016). The gene discussed is CTLA4; the disease is metastatic melanoma.